Vistagen Therapeutics Faces Class Action Lawsuit with Deadline for Lead Plaintiff by March 16, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Vistagen Therapeutics (NASDAQ: VTGN) common stock between April 1, 2024, and December 16, 2025, with a deadline of March 16, 2026, for those wishing to serve as lead plaintiff and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding Vistagen's drug fasedienol, leading investors to purchase shares at artificially inflated prices, resulting in financial losses when the truth emerged.
- Law Firm's Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, underscoring its capability and experience in handling such cases effectively.
- Investor Action Guidance: Investors are encouraged to visit the Rosen Law Firm website or call the toll-free number for more information on joining the class action, ensuring they select qualified legal counsel to protect their interests before the class is certified.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTGN is 15.50 USD with a low forecast of 12.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.671
Low
12.00
Averages
15.50
High
19.00
Current: 0.671
Low
12.00
Averages
15.50
High
19.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
